✦ LIBER ✦

The effect of LAK cells and recombinant interleukin-2 in advanced bladder cancer: an experimental and clinical study

✍ Scribed by Steven, K.; Geertsen, P.; Hermann, G.; Tromholt, V.; Kieler, J.; von der Maase, H.; van der Plas, J.; Palmer, P.; Franks, C.R.

Book ID: 123428813
Publisher: Elsevier Science
Year: 1989
Tongue: English
Weight: 63 KB
Volume: 16
Category: Article
ISSN: 0305-7372
DOI: 10.1016/0305-7372(89)90039-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An explanation of the variable clinical

An explanation of the variable clinical response to interleukin 2 and LAK cells

✍ Giorgio Parmiani 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 830 KB

Toxicity of local, continuous and cyclic

Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder

✍ Hartwig Schwaibold; Edith Huland; Hans Heinzer; Udo Schwuléra; Hartwig Huland 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 876 KB

Lack of correlation between peripheral b

Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

✍ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t

Malignant plasma cells are sensitive to

Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma

✍ David J. Gottlieb; H. Grant Prentice; Atul B. Mehta; Andrew R. Galazka; Helen E. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Continuous intra-arterial administration

Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study

✍ Andrea Tubaro; Carlo Vicentini; Pia C. Bossola; Paolo Galassi; Lucio Miano; Fran 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 589 KB

Modifications of plasma lipids, lipoprot

Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells

✍ C.L. Malmendier; J-F. Lontie; J.P. Sculier; D.Y. Dubois 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 660 KB